

# NYRx Brand Less Than Generic Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **May 1, 2025**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Acular LS™, Brovana®, Carbatrol®, Cipro® oral suspension, Oxtellar XR™, Targretin® gel, Tegretol® tablet, and Xarelto® 2.5mg tablet** will be **ADDED** to the program.
- **Oseni® and Onglyza®** will be **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

## NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
<b>Acular LS™</b>	Epipen	Sandostatin LAR®
Advair Diskus®	Epipen, JR	Spiriva® HandiHaler®
Advair HFA®	Farxiga®	Sprycel®
Alphagan P® 0.15%	Forteo®	Symbicort®
Alphagan P® 0.1%	Glumetza®	<b>Targretin® gel</b>
Apriso®	Istalol®	Tegretol® suspension
Azopt™	Kitabis® Pak	<b>Tegretol® tablet</b>
Bethkis®	Myrbetriq®	Tegretol® XR
<b>Brovana®</b>	Nexavar®	Trileptal® suspension
Carbaglu®	NuvaRing®	Ventolin® HFA
<b>Carbatrol®</b>	<b>Oxtellar XR™</b>	Victoza®
Cellcept® suspension	Pentasa®	Votrient®
<b>Cipro® oral suspension</b>	Pradaxa®	Vyvanse® capsule
Combigan®	Protonix® suspension	<b>Xarelto® 2.5mg tablet</b>
Copaxone® 20mg SQ	Pylera®	Xigduo® XR
Daytrana®	Restasis®	Xopenex HFA®
Depakote® Sprinkle	Retin-A® cream	Zavesca®
Dymista®	Risperdal Consta®	

\* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.